作者: Jorge Rojas-Rivera , Alberto Ortiz , Jesus Egido
DOI: 10.1155/2012/321714
关键词:
摘要: Drugs targeting the renin-angiotensin-aldosterone system (RAAS) are mainstay of therapy to retard progression proteinuric chronic kidney disease (CKD) such as diabetic nephropathy. However, nephropathy is still first cause end-stage renal disease. New drugs targeted pathogenesis and mechanisms these diseases beyond RAAS inhibition needed. There solid experimental evidence a key role oxidative stress its interrelation with inflammation on damage. randomized well-powered trials agents in CKD scarce. We now review biological bases diseases, focus nephropathy, well Keap1-Nrf2 pathway recent clinical this bardoxolone methyl.